Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380566 | 0.88 | TAAR1 (0.75) | TAAR1MAOBLTA4HEPHX2LOXL2 | |
| SCHEMBL1319643 | 0.88 | TAAR1 (0.73) | TAAR1MAOBLOXL2 | |
| Hydrochloric Acid SCHEMBL2149447 | 0.86 | TAAR1 (0.70) | TAAR1MAOBLOXL2 | |
| SCHEMBL2025420 | 0.82 | MAOA (0.57) | LTA4H | |
| SCHEMBL3706426 | 0.81 | TAAR1 (0.70) | TAAR1MAOBLOXL2 | |
| SCHEMBL12721466 | 0.81 | FFAR1 (0.50) | LTA4HEPHX2 | |
| Hydrochloric Acid SCHEMBL7393435 | 0.79 | TAAR1 (0.67) | TAAR1MAOBLOXL2 | |
| SCHEMBL919783 | 0.79 | LOXL2 (0.73) | TAAR1MAOBLTA4HEPHX2LOXL2 | |
| SCHEMBL21726316 | 0.79 | TAAR1 (0.67) | TAAR1MAOBLOXL2 | |
| SCHEMBL7005631 | 0.79 | TAAR1 (0.67) | TAAR1MAOBLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649053-B1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LTD (GB) | 2015-11-04 | — | — | EP | disclosed |
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20140113922-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-04-24 | — | — | US | disclosed |
| US-8637536-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-01-28 | — | — | US | disclosed |
| EP-2649053-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | Glaxo Group Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2012076435-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2 | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-8153638-B2 | Metabotropic glutamate-receptor-potentiating isoindolones | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| WO-2011078370-A1 | NOVEL PARABANIC ACID DERIVATIVE AND DRUG HAVING THE SAME AS ACTIVE INGREDIENT | 杏林製薬株式会社 (JP) | 2011-06-30 | — | — | WO | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20100317674-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | VAN WAGENEN BRADFORD | 2010-12-16 | — | — | US | disclosed |
| US-7807706-B2 | Metabotropic glutamate-receptor-potentiating isoindolones | ASTRAZENECA AB (SE) | 2010-10-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113922-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | TAAR1 3528/4885MAOB 991/4885LTA4H 15/4885 |
| US-20100317674-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | GRM1, GRIN1, GRM2 | TAAR1 219/4885MAOB 3122/4885LTA4H 2964/4885 |
| US-20120142717-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | TAAR1 3528/4885MAOB 991/4885LTA4H 15/4885 |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | TAAR1 286/4885MAOB 3508/4885LTA4H 1963/4885 |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | TAAR1 2015/4885MAOB 840/4885LTA4H 14/4885 |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | GRM1, GRIN1, GRM2 | TAAR1 219/4885MAOB 3122/4885LTA4H 2964/4885 |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | TAAR1 1985/4885MAOB 861/4885LTA4H 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.